Discovers and develops drug candidates for epilepsy, depression and pain for patients with neurological and psychiatric disorders.
10-K for FY2025, filed Feb 26, 2026
Collaboration partners pay for licenses and research and development services; agreements may provide upfront payments, research funding, milestone payments and royalties.
10-K for FY2025, filed Feb 26, 2026
$7.5M
10-K for FY2025, filed Feb 26, 2026
$7.5M ↗
Collaboration partners and licensees provide research funding and may receive licenses or research and development services under collaboration agreements.
10-K for FY2025, filed Feb 26, 2026
No. It lost $345.9M in FY2025.
Shrinking. Revenue fell 59% in 4 years, from $18.4M in FY2021 to $7.5M in FY2025, about 20% a year.
Broader mood-disorder work
The older report described an MDD program; the latest report also describes azetukalner development for bipolar depression.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026Based on promising pre-clinical data with XEN1101 and published clinical data generated using ezogabine, we are evaluating the clinical…View ↗
We continue to explore the applicability of azetukalner in neuropsychiatric disorders based on establishing a strong scientific rationale…View ↗
Pain drug candidates
The earlier report described the pipeline as focused on epilepsy; the latest report also describes potassium- and sodium-channel drug candidates being developed for pain.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical stage biopharmaceutical company committed to delivering innovative therapeutics to improve the lives of patients with…View ↗
We continue to expand our portfolio by leveraging our extensive ion channel expertise to discover and develop potassium and sodium channel…View ↗
Competes with Biohaven, Jazz Pharmaceuticals, Neurona Therapeutics, NeuShen Therapeutics, Otsuka Pharmaceutical, Praxis Precision Medicines, QurAlis, Rapport Therapeutics, SK Life Science, Supernus Pharmaceuticals, Zhimeng Biopharma, AbbVie, Alto Neuroscience, Axsome Therapeutics, Johnson & Johnson, Neumora Therapeutics, Neurocrine Biosciences, Vanda Pharmaceuticsals, Autobahn Therapeutics, and Eli Lilly and
10-K for FY2025, filed Feb 26, 2026If one or more of our proprietary or partnered product candidates is approved for the treatment of epilepsy, we anticipate that they could…View ↗
Loading...